Teva reaches proposed $4.25 bln settlement of U.S. opioid lawsuits - Reuters
Tweet
Share
E-mail
Get Alerts TEVA Hot Sheet
Price: $40.06 +2.77%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.1%
EPS Growth %: -11.5%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.1%
EPS Growth %: -11.5%
Join SI Premium – FREE
Teva reaches proposed $4.25 bln settlement of U.S. opioid lawsuits - Reuters
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Iambic Therapeutics (IAM) files for proposed IPO
- Bergeron challenges Ethan Allen's CEO succession plan ahead of vote
- Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophren
Create E-mail Alert Related Categories
Corporate News, Hot Corp. News, Litigation, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
